This quarterly report represents an surprise of 1.56%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.70 per share when it actually produced a loss of $2.27, delivering a surprise of -33.53%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Clovis, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $37.60 million for the quarter ended September 2019, surpassing the Zacks Consensus Estimate by 3.56%. This compares to year-ago revenues of $22.76 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future expectations will mostly depend on management's commentary on the call.
Clovis shares have lost about 80% since the beginning of the year versus the S&P 500's gain of 22.7%.
Sign Up for our 100% Free Email Newsletter:
Text Message Alerts ---> text 'PS101' to 67076
(It's FREE, however Msg&Data rates may apply.)